Publicaciones en colaboración con investigadoras/es de Hospital Universitario Araba (27)

2023

  1. Correction: Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection (Trials, (2021), 22, 1, (851), 10.1186/s13063-021-05777-6)

    Trials

2022

  1. Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens

    AIDS (London, England), Vol. 36, Núm. 15, pp. 2107-2119

2021

  1. Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection

    Trials, Vol. 22, Núm. 1

2020

  1. Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients

    AIDS (London, England), Vol. 34, Núm. 10, pp. 1497-1507

2019

  1. Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain

    Frontiers in Microbiology, Vol. 10, Núm. APR

  2. Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients

    AIDS, Vol. 33, Núm. 2, pp. 269-278

2018

  1. A case-control study of non-AIDS-defining cancers in a prospective cohort of HIV-infected patients

    Medicina Clinica, Vol. 150, Núm. 8, pp. 291-296

  2. Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort

    AIDS (London, England), Vol. 32, Núm. 16, pp. 2405-2416

  3. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients

    AIDS, Vol. 32, Núm. 11, pp. 1423-1430

2012

  1. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial

    Journal of Infectious Diseases, Vol. 206, Núm. 6, pp. 961-968

2011

  1. Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/Hepatitis C virus-coinfected patients treated for chronic hepatitis C

    Clinical Infectious Diseases, Vol. 53, Núm. 12, pp. 1291-1295

2010

  1. Factores asociados con la no realización de la prueba de la tuberculina en una cohorte de pacientes VIH positivos

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 28, Núm. 4, pp. 215-221

  2. Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C

    AIDS Research and Human Retroviruses, Vol. 26, Núm. 4, pp. 419-424

2009

  1. Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain

    BMC Infectious Diseases, Vol. 10

  2. Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine

    Current HIV Research, Vol. 7, Núm. 5, pp. 526-532

  3. Nephrogenic systemic fibrosis in a patient with a p-ANCA systemic vasculitis

    Reumatologia Clinica, Vol. 5, Núm. 6, pp. 264-267

2008

  1. Diabetes mellitus during interferon therapy

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 26, Núm. 2, pp. 120-121

  2. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C

    AIDS, Vol. 22, Núm. 1, pp. 15-21

2007

  1. Prevalence of M. tuberculosis infection and tuberculosis disease among HIV-infected people in Spain

    International Journal of Tuberculosis and Lung Disease, Vol. 11, Núm. 11, pp. 1196-1202

  2. Rickettsia monacensis and human disease, Spain

    Emerging Infectious Diseases, Vol. 13, Núm. 9, pp. 1405-1407